Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke

TARDIS (ISRCTN47823388)

The 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial is a collaborative, international, multicentre, prospective, randomised, blinded endpoint, parallel-group, controlled trial designed to test the safety and efficacy of adding clopidogrel to aspirin and dipyridamole in patients with acute ischaemic stroke or TIA

5000 patients with acute ischaemic stroke or complex TIA will be enrolled within 48 hours of onset and treatment will be given for 30 days. The primary outcome is death or dependency (modified Rankin Scale) and will be determined at 90 days by observers blinded to treatment. Initially, a start-up phase, funded by BHF, in 350 patients in the UK will test safety, feasibility and tolerability.

If you are interested in having your centre join the trial, please fill in an Expression of Interest form and send/fax to the Coordinating Centre as per details at bottom of form.
2010, February: CT/MR Imaging data must now only be submitted using the TARDIS website Upload facility; please do not submit data on CD/DVDs to protect patient confidentiality in case media get lost in the post. TARDIS will be at International Stroke Conference (San Antonio, USA). May: TARDIS will be at European Stroke Conference (Barcelona, Spain).

TARDIS trial website and database

Enter LIVE TARDIS trial web-site


Status

As of 31 January 2010:

Enrolled patients: 38 - ischaemic stroke 25 (66%), TIA 13 (34%)

Active centres: 11

Over 50 centres have agreed to join the start-up phase of the trial.

Approvals: MHRA, MREC, ISRCTN, UK SRN adoption, local R+D


Funding


Forthcoming events

TARDIS will be present at:

News


Documents

Newsletter 1 - December 2009 (PDF file)


Presentations/publications/listings/media


Demo/practice website and database

Enter DEMO TARDIS demonstration/practice trial web-site


Study personnel

Trial Steering Committee:
Helen Rodgers (Newcastle, Independent Chair), Independent experts - to be appointed, Philip Bath (Nottingham, Chief Investigator), Stan Heptinstall (Nottingham), Hugh Markus (London), Ossie Newell (Nottingham, Patient representative), Tom Robinson (Leicester), Graham Venables (Sheffield), Representative of University of Nottingham/sponsor - to be appointed
Trial Management Committee (Nottingham):
Philip Bath (Chair), Margaret Adrian (Nurse Coordinator), Tim England (Medic), Chamila Geeganage (Medic), Michael Tracy (Statistician), Wim Clarke (Financial), Sue Williams (Secretary)
Independent Data Monitoring Committee:
Ian Ford (Glasgow, Chair), Cathie Sudlow (Edinburgh), Matthew Walters (Glasgow)
Independent Events Adjudicator:
Niki Sprigg (Nottingham)
Neuroimaging Adjudicators:
Jenny Becker
Transcranial doppler substudy:
PI: Hugh Markus (London)
Platelet substudy:
PI: Stan Heptinstall (Nottingham)
Programming/database management:
Graham Watson, Liz Walker (UK)

Contact details

TARDIS Trial Office
Division of Stroke Medicine
Institute of Neuroscience
University of Nottingham
Clinical Sciences Building
City Hospital campus
Hucknall Road
Nottingham NG5 1PB
UK
 
Telephone: +44 115 823 0210
Fax: +44 115 823 0273
E-mail: tardis@nottingham.ac.uk

Written by Philip Bath, last updated 3 February 2010

Valid HTML 4.01 Transitional